A dual GIP/GLP-1 receptor agonist with a large Phase 3 program (SURPASS, SURMOUNT) and approved labeling.
Tirzepatide is a single engineered molecule that activates two gut-hormone receptors at once — GIP and GLP-1. GLP-1 is the same satiety-and-insulin pathway semaglutide uses; GIP is a second incretin hormone that also influences insulin release and how the body handles fat and energy. Combining both in one molecule is the central idea.
By engaging both receptors it amplifies what GLP-1 does alone: more glucose-dependent insulin, stronger appetite suppression, and slower gastric emptying. Researchers also believe it is 'biased' at the GLP-1 receptor (favoring one internal signaling route) while fully activating GIP, and that this particular balance helps explain why it tends to outperform GLP-1-only drugs on weight in head-to-head data.
Like semaglutide, a fatty-acid tail lets it bind albumin for a multi-day half-life and weekly dosing. It's approved for type 2 diabetes and obesity on the strength of the SURPASS and SURMOUNT programs. The main limitation is GI tolerability during dose escalation, and it shares the GLP-1 class C-cell precaution.
Searching the published record…
Searching the published record…
Searching the published record…
Studies are surfaced live from the U.S. National Library of Medicine (PubMed). biohackr indexes and links the published record; it does not host or alter source articles.